Biomarkers of colorectal cancer: Recent advances and future challenges

Proteomics - Clinical Applications

Volumn 9, Issue 1-2, 2015, Pages 64-71

  Coghlin, Caroline ^a   Murray, Graeme I ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Biomarker; Colorectal cancer; Diagnosis; Immunohistochemistry; Predictive; Prognosis

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANNEXIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOCHROME P450; DASATINIB; IMATINIB; MATRIX METALLOPROTEINASE; PANITUMUMAB; PROTEOME; TUMOR MARKER; TUMOR PROTEIN;

BLOOD SAMPLING; CANCER STAGING; CANCER TISSUE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; PROGNOSIS; PROTEOMICS; REVIEW; SCREENING; TREATMENT RESPONSE; ANIMAL; COLORECTAL NEOPLASMS; METABOLISM;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM PROTEINS; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84922948849     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400082     Document Type: Review

References (60)

1. Ferlay, J., Shin, H. R., Bray, F., Forman, D. et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
2. Jemal, A., Bray, F., Center, M. M., Ferlay, J. et al., Global cancer statistics. CA Cancer. J. Clin. 2011, 61, 69-90.
3. Hewitson, P., Glasziou, P., Watson, E., Towler, B., Irwig, L., Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol. 2008, 103, 1541-1549.
4. Elmunzer, B. J., Hayward, R. A., Schoenfeld, P. S., Saini, S. D. et al., Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2012, 9, e1001352.
5. Brenner, H., Kloor, M., Pox, C. P., Colorectal cancer. Lancet 2014, 383, 1490-1502.
6. Coghlin, C., Murray, G. I., Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics 2013, 13, 2227-2228.
7. Luo, Y., Wang, L., Wang, J., Developing proteomics-based biomarkers for colorectal neoplasms for clinical practice: opportunities and challenges. Proteomics Clin. Appl. 2013, 7, 30-41.
8. Martinez-Aguilar, J., Chik, J., Nicholson, J., Semaan, C. et al., Quantitative mass spectrometry for colorectal cancer proteomics. Proteomics Clin. Appl. 2013, 7, 42-54.
9. Coghlin, C., Murray, G. I., Following the protein biomarker trail to colorectal cancer. Colorectal Cancer 2012, 1, 93-96.
10. Werling, R. W., Yaziji, H., Bacchi, C. E., Gown, A. M., CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am. J. Surg. Pathol. 2003, 27, 303-310.
11. de Wit, M., Fijneman, R. J., Verheul, H. M., Meijer, G. A., Jimenez, C. R., Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin. Biochem. 2013, 46, 466-479.
12. Wang, J., Wang, X., Lin, S., Chen, C. et al., Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One 2013, 8, e70519.
13. Qiu, Y., Patwa, T. H., Xu, L., Shedden, K. et al., Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectinglycoarray and lectin blot. J. Proteome Res. 2008, 7, 1693-1703.
14. Roeise, O., Sivertsen, S., Ruud, T. E., Bouma, B. N. et al., Studies on components of the contact phase system in patients with advanced gastrointestinal cancer. Cancer 1990, 65, 1355-1359.
15. Manna, S. K., Tanaka, N., Krausz, K. W., Haznadar, M. et al., Biomarkers of coordinate metabolic reprogramming in colorectal tumors in mice and humans. Gastroenterology 2014, 146, 1313-1324.
16. Soreide, K., Gudlaugsson, E., Skaland, I., Janssen, E. A. et al., Metachronous cancer development in patients with sporadic colorectal adenomas-multivariate risk model with independent and combined value of hTERT and survivin. Int. J. Colorectal Dis. 2008, 23, 389-400.
17. Comoglio, P. M., Trusolino, L., Cancer: the matrix is now in control. Nat. Med. 2005, 11, 1156-1159.
18. Sleeman, J. P., Christofori, G., Fodde, R., Collard, J. G. et al., Concepts of metastasis in flux: the stromal progression model. Semin. Cancer Biol. 2012, 22, 174-186.
19. Coghlin, C., Murray, G. I., Current and emerging concepts in tumour metastasis. J. Pathol. 2010, 222, 1-15.
20. Coghlin, C., Murray, G. I., The role of gene regulatory networks in promoting cancer progression and metastasis. Future Oncol. 2014, 10, 735-748.
21. Sveen, A., Agesen, T. H., Nesbakken, A., Meling, G. I. et al., ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin. Cancer Res. 2012, 18, 6001-6010.
22. Salazar, R., Roepman, P., Capella, G., Moreno, V. et al., Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 2011, 29, 17-24.
23. Maak, M., Simon, I., Nitsche, U., Roepman, P. et al., Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann. Surg. 2013, 257, 1053-1058.
24. Deschoolmeester, V., Baay, M., Specenier, P., Lardon, F., Vermorken, J. B., A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010, 15, 699-731.
25. Coghlin, C., Carpenter, B., Dundas, S. R., Lawrie, L. C. et al., Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J. Pathol. 2006, 210, 351-357.
26. Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T., Fothergill, J. E., Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 1996, 2, 461-462.
27. Kumarakulasingham, M., Rooney, P. H., Dundas, S. R., Telfer, C. et al., Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res. 2005, 11, 3758-3765.
28. Curran, S., Dundas, S. R., Buxton, J., Leeman, M. F. et al., Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin. Cancer Res. 2004, 10, 8229-8234.
29. O'Dwyer, D., Ralton, L. D., O'Shea, A., Murray, G. I., The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 2011, 6, e27718.
30. Duncan, R., Carpenter, B., Main, L. C., Telfer, C., Murray, G. I., Characterisation and protein expression profiling of annexins in colorectal cancer. Br. J. Cancer 2008, 98, 426-433.
31. Peng, Y., Li, X., Wu, M., Yang, J. et al., New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer. Mol. Biosyst. 2012, 8, 3077-3088.
32. Besson, D., Pavageau, A. H., Valo, I., Bourreau, A. et al., A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol. Cell. Proteomics 2011, 10, M111.009712.
33. Meding, S., Balluff, B., Elsner, M., Schone, C. et al., Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J. Pathol. 2012, 228, 459-470.
34. Croner, R. S., Sturzl, M., Rau, T. T., Metodieva, G. et al., Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis. Int. J. Cancer 2014, 135, 2878-2886
35. Jankova, L., Chan, C., Fung, C. L., Song, X. et al., Proteomic comparison of colorectal tumours and nonneoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol. Biosyst. 2011, 7, 2997-3005.
36. Tan, K. L., Jankova, L., Chan, C., Fung, C. L. et al., Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology 2011, 59, 1057-1070.
37. Jankova, L., Robertson, G., Chan, C., Tan, K. L. et al., Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. BMC Cancer 2012, 12, 196-2407-12-196.
38. Carroll, M., Seaman, H., Halloran, S., Tests and investigations for colorectal cancer screening. Clin. Biochem. 2014, 47, 921-939.
39. van Dam, L., Kuipers, E. J., Steyerberg, E. W., van Leerdam, M. E., de Beaufort, I. D., The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies? Lancet Oncol. 2013, 14, e38-e46.
40. Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R. et al., Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 2014, 370, 1287-1297.
41. Schwarzenbach, H., Hoon, D. S., Pantel, K., Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer. 2011, 11, 426-437.
42. Yang, I. P., Tsai, H. L., Huang, C. W., Huang, M. Y. et al., The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One 2013, 8, e66842.
43. Toiyama, Y., Takahashi, M., Hur, K., Nagasaka, T. et al., Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. Cancer Inst. 2013, 105, 849-859.
44. da Silva Filho, B. F., Gurgel, A. P., Neto, M. A., de Azevedo, D. A. et al., Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J. Clin. Pathol. 2013, 66, 775-778.
45. Iinuma, H., Watanabe, T., Mimori, K., Adachi, M. et al., Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol. 2011, 29, 1547-1555.
46. Galizia, G., Gemei, M., Orditura, M., Romano, C. et al., Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J. Gastrointest. Surg. 2013, 17, 1809-1818.
47. Kin, C., Kidess, E., Poultsides, G. A., Visser, B. C., Jeffrey, S. S., Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev. Mol. Diagn. 2013, 13, 581-599.
48. Reumer, A., Maes, E., Mertens, I., Cho, W. C. et al., Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare? Expert Rev. Proteomics 2014, 11, 449-463.
49. Uzozie, A., Nanni, P., Staiano, T., Grossmann, J. et al., Sorbitol dehydrogenase overexpression and other aspects of dysregulated protein expression in human precancerous colorectal neoplasms: a quantitative proteomics study. Mol. Cell. Proteomics 2014, 13, 1198-1218.
50. Choi, J. W., Liu, H., Shin, D. H., Yu, G. I. et al., Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics 2013, 13, 2361-2374.
51. Pengjun, Z., Xinyu, W., Feng, G., Xinxin, D. et al., Multiplexed cytokine profiling of serum for detection of colorectal cancer. Future Oncol. 2013, 9, 1017-1027.
52. Albrethsen, J., Bogebo, R., Moller, C. H., Olsen, J. A. et al., Candidate biomarker verification: Critical examination of a serum protein pattern for human colorectal cancer. Proteomics Clin. Appl. 2012, 6, 182-189.
53. Chen, H., Werner, S., Tao, S., Zoernig, I., Brenner, H., Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett. 2014, 346, 178-187.
54. Pierobon, M., Silvestri, A., Spira, A., Reeder, A. et al., Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: Evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J. Proteome Res. 2014, 13, 2846-2855.
55. McKinley, E. T., Liu, H., McDonald, W. H., Luo, W. et al., Global phosphotyrosine proteomics identifies PKCdelta as a marker of responsiveness to Src inhibition in colorectal cancer. PLoS One 2013, 8, e80207.
56. Turtoi, A., Blomme, A., Debois, D., Somja, J. et al., Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology 2014, 59, 924-934.
57. Emmink, B. L., Verheem, A., Van Houdt, W. J., Steller, E. J.et al., The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J. Proteomics 2013, 91, 84-96.
58. Knol, J. C., de Wit, M., Albrethsen, J., Piersma, S. R. et al., Proteomics of differential extraction fractions enriched for chromatin-binding proteins from colon adenoma and carcinoma tissues. Biochim. Biophys. Acta 2014, 1844, 1034-1043.
59. Katsuda, T., Kosaka, N., Ochiya, T., The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers. Proteomics 2014, 14, 412-425.
60. Greening, D. W., Kapp, E. A., Ji, H., Speed, T. P., Simpson, R. J., Colon tumoursecretopeptidome: insights into endogenous proteolytic cleavage events in the colon tumour microenvironment. Biochim. Biophys. Acta 2013, 1834, 2396-2407.